Compare Amphastar Pharmaceuticals Inc (AMPH) vs Dolby Laboratories, Inc. (DLB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Dolby Laboratories, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Dolby Laboratories, Inc. trades at $50.11 (market cap $4.71B). The key difference: Dolby Laboratories, Inc. is far larger — about 5.7× Amphastar Pharmaceuticals Inc's market cap, and Dolby Laboratories, Inc. pays a 2.83% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DLB | |
|---|---|---|
Market Cap | $826.08M | $4.71B |
Sector | Health | Industrials |
52-Week High | $30.81 | $76.79 |
52-Week Low | $16.87 | $49.31 |
Enterprise Value | $1.22B | $4.17B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
DLB trades at $49.8, down 0.64% on the day, with a bearish technical outlook but strong fundamentals. Recent earnings beats, including Q1 2026 EPS of $1.37 versus $1.31 expected, highlight operational strength. The company maintains high gross margins of 87.44% and positive cash flow, supported by licensing growth and expanding Dolby Atmos adoption.
The stock presents a value opportunity with a P/E of 19.76 below historical averages, and a consensus price target of $87.50 implies significant upside. Risks include cyclical end-market exposure and potential dilution from pipeline developments. Analyst sentiment is moderately bullish, but technical indicators suggest near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →
